Brief: TG Therapeutics Completes Enrollment In The Phase 3 Enhance Trial Evaluating Its New Simplified Dosing Schedule For Briumvi
28/10/2025 12:09
Oct 28 (Reuters) - TG Therapeutics Inc TGTX.O: TG THERAPEUTICS COMPLETES ENROLLMENT IN THE PHASE 3 ENHANCE TRIAL EVALUATING ITS NEW SIMPLIFIED DOSING SCHEDULE FOR BRIUMVI Source text: ID:nGNX6Sl9QJ Further company coverage: TGTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on TG Therapeutics
See all newsTG Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tg Therapeutics Reports Second Quarter 2026 Financial Results And Raises Briumvi® Revenue Guidance
TG Therapeutics Q2 product revenue rises 70% on BRIUMVI sales
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj